Evidence map›Paper›PMID 21606957›Full record

Trial reportLeukemia2011

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.

R A Wilcox, K Ristow, T M Habermann, D J Inwards, I N M Micallef, P B Johnston, J P Colgan, G S Nowakowski, S M Ansell, T E Witzig and 2 more

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03000738 (The Value and Potential Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Non-Hodgkin Lymphomas.), which is not on this map. Cited by 94 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03000738 unknown statusnot on this mapstarted 2016, after this paper: background citation

The Value and Potential Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Non-Hodgkin Lymphomas.

TypeobservationalSponsorPeking Union Medical College HospitalRan2016 to 2019Enrolled100ConditionsLymphoma,Non-Hodgkin, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Immunity and Beyond: Emerging Roles of Monocytes and Macrophages in Cancer.Advances in experimental medicine and biology · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Prognostic significance of diffuse increased fluorine-18-fluorodeoxyglucose (Quantitative imaging in medicine and surgery · 2024
    Article
  14. Review
  15. Article
  16. Article
  17. Frontiers in immunology · 2024
    Article
  18. Article
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

R A WilcoxDepartment of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. wilcox.ryan@mayo.edu
K Ristow
T M Habermann
D J Inwards
I N M Micallef
P B Johnston
J P Colgan
G S Nowakowski
S M Ansell
T E Witzig
S N Markovic
L Porrata

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the use of modern immunochemotherapy regimens, almost 50% of patients with diffuse large-B-cell lymphoma will relapse. Current prognostic models, including the International Prognostic Index, incorporate patient and tumor characteristics. In contrast, recent observations show that variables related to host adaptive immunity and the tumor microenvironment are significant prognostic variables in non-Hodgkin lymphoma. Therefore, we retrospectively examined the absolute monocyte and lymphocyte counts as prognostic variables in a cohort of 366 diffuse large-B-cell lymphoma patients who were treated between 1993 and 2007 and followed at a single institution. The absolute monocyte and lymphocyte counts in univariate analysis predicted progression-free and overall survival when analyzed as continuous and dichotomized variables. On multivariate analysis performed with factors included in the IPI, the absolute monocyte and lymphocyte counts remained independent predictors of progression-free and overall survival. Therefore, the absolute monocyte and lymphocyte counts were combined to generate a prognostic score that identified patients with an especially poor overall survival. This prognostic score was independent of the IPI and added to its ability to identify high-risk patients.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansLymphocytesLymphoma, Large B-Cell, DiffuseMaleMiddle AgedMonocytesNeoplasm StagingPrognosisRetrospective StudiesRisk FactorsSurvival Rate

Identifiers

PMID21606957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.